Exchange: NYSE·Updated 07:31 PM EDT

BIO News

News
all
press releases
Neogen (NEOG) Q1 Earnings and Revenues Beat Estimates
Neogen (NEOG) delivered earnings and revenue surprises of +60.00% and +7.07%, respectively, for the quarter ended August 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Neogen (NEOG) Q1 Earnings and Revenues Beat Estimates
Neogen (NEOG) delivered earnings and revenue surprises of +60.00% and +7.07%, respectively, for the quarter ended August 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
Biodesix Expands MRD Testing With Tumor-Informed and Tumor-Naive Tests
BDSX advances two blood-based MRD programs with Bio-Rad and Thermo Fisher to broaden access to cancer monitoring.
Zacks
Here's Why You Should Hold Bio-Rad Stock in Your Portfolio for Now
BIO's Clinical Diagnostics strength and international reach support growth, while China weakness, geopolitics and FX remain key risks.
Zacks
Bio-Rad to Participate in Fireside Chat During Bernstein Insights Healthcare Leaders and Disruptors 3rd Annual Forum
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Bernstein Insights Healthcare Leaders and Disruptors...
Business Wire
Why Is Insulet (PODD) Up 8.1% Since Last Earnings Report?
Insulet (PODD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Bio-Rad (BIO) Up 11.7% Since Last Earnings Report: Can It Continue?
Bio-Rad (BIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Bio-Rad to Participate in Fireside Chat During Wells Fargos 21st Annual Healthcare Conference
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Financial Officer, Roop K. Lakkaraju, will participate in a fireside chat event during Wells Fargos 21st Annual Healthcare Conference on...
Business Wire
Is Bio-Rad a Buy as Digital PCR Growth Meets a Premium Valuation?
BIO's digital PCR gains and recurring diagnostics base support growth, but a 40.2X forward P/E and muted 2026 outlook keep valuation risk in focus.
Zacks
Bio-Rad Gains 19.1% in the Past Month: Can Its Momentum Keep Building?
BIO's 19.1% monthly rally is backed by digital PCR gains and steadier diagnostics, but weak Life Science demand and a rich valuation loom.
Zacks
Don't Overlook Bio-Rad (BIO) International Revenue Trends While Assessing the Stock
Explore Bio-Rad's (BIO) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
Zacks

Advertisement|Remove ads.